

Table 1. Patient characteristics in the QUEST-RA study per country.

Country	# sites	# patients	Female %	Non-Caucasians %	Age, mean	Education years mean	BMI, female mean	BMI, male mean	Disease Duration years mean	RF+ %	Extra-articular Disease* %
1- Denmark	3	301	76.7	1.7	57.8	10.73	24.6	25.5	12.0	73.7	33.9
2- Finland	3	304	72.4	0.3	58.5	10.36	26.7	26.5	13.5	75.1	17.8
3- France	4	389	77.9	6.7	55.3	10.86	24.8	25.2	12.8	75.3	20.6
4- Germany	3	225	83.6	1.3	58.8	10.40	26.1	27.6	13.4	61.4	35.6
5- Ireland	3	225	64.3	3.1	56.7	11.59	25.3	25.5	11.5	81.0	29.9
6- Italy	4	336	78.2	0.9	61.0	8.34	25.2	26.0	10.5	72.7	13.0
7- Netherlands	3	317	66.2	4.1	59.2	11.26	26.0	25.2	9.2	68.8	12.9
8- Poland	7	642	86.7	0.6	53.2	12.02	25.4	25.3	11.5	70.8	33.5
9- Spain	3	301	74.3	2.0	59.9	10.38	26.3	26.8	10.8	71.4	22.9
10- Sweden	3	248	72.1	1.2	59.5	10.42	25.2	25.3	12.4	82.0	22.6
11- UK	3	126	77.8	16.7	60.2	12.71	24.7	25.8	15.5	84.4	30.4
12- Turkey	3	309	85.6	2.9	51.9	7.37	27.3	26.4	11.6	68.7	18.1
13- Serbia	1	100	88.0	0	59.2	8.55	25.9	24.6	10.1	71.4	23.0
14- USA	3	294	72.3	32.4	57.4	13.49	28.2	27.9	9.3	69.9	24.1
15- Argentina	2	246	90.2	93.9	51.4	9.42	26.3	25.2	9.9	90.5	26.5
Total	48	4363	78.0	9.8	56.8	10.66	25.9	26.0	11.5	73.7	24.4

**includes nodules, pulmonal fibrosis, pericarditis, Felty's, scleritis

A supplemental file including standard deviations of variables provided.

Table 2. Median values of clinical variables in the QUEST-RA study per country.

Country	ESR	SJC28	TJC28	LIM28	MDGlobal	HAQ	MDHAQ	Pain	Global	Fatigue	DAS28	%am15*
Denmark	14.0	1.0	2.0	0.0	1.3	0.63	0.50	2.6	2.8	3.6	3.3	56%
Finland	13.0	1.0	1.0	0.0	0.9	0.63	0.50	2.8	2.8	2.6	3.1	66%
France	16.0	1.0	2.0	1.0	2.5	0.88	0.60	3.9	3.6	4.2	3.6	60%
Germany	20.0	3.0	4.0	0.0	3.0	0.75	0.60	5.0	4.9	4.6	4.3	56%
Ireland	18.0	3.0	4.0	2.0	1.6	0.75	0.70	3.4	2.9	3.5	4.0	55%
Italy	28.0	2.0	4.0	0.0	3.0	1.06	0.80	4.9	5.0	4.9	4.5	51%
Netherlands	15.0	1.0	0.0	1.0	0.6	0.75	0.60	2.5	2.7	3.1	3.0	49%
Poland	31.0	6.0	9.0	3.0	4.3	1.38	1.20	5.0	4.8	5.2	5.3	78%
Spain	17.0	1.0	1.0	0.0	1.2	0.88	0.72	3.2	3.6	3.7	3.5	47%
Sweden	19.0	2.0	2.0	1.0	1.3	0.88	0.70	3.3	3.3	3.7	3.6	67%
UK	21.0	1.0	4.0	0.0	2.0	0.88	0.70	4.2	3.8	5.1	4.2	65%
Turkey	30.0	0.0	2.5	0.0	2.0	0.88	0.70	4.2	4.6	4.5	4.1	53%
Serbia	28.0	6.0	18.0	2.0	4.6	1.63	1.40	5.1	5.3	5.5	6.1	71%
USA	14.0	2.0	1.0	0.0	1.9	0.63	0.56	3.3	2.6	3.2	3.2	58%
Argentina	30.0	9.0	10.5	2.0	4.6	1.00	0.90	5.0	4.7	6.3	5.6	64%
Total	21.0	2.0	3.0	1.0	2.2	0.88	0.70	4.0	4.0	4.4	4.0	61%

*percentage of patients who report morning stiffness 15 minutes or more

ESR=Erythrocyte sedimentation rate; SJC=Swollen joint count, TJC=Tender joint count, LIM=Limited motion/Deformity joint count, MDGlobal=Doctor global assessment of disease activity, HAQ= health assessment questionnaire, MDHAQ=Multi-dimensional HAQ, DAS28=Disease activity score on 28 joint count

A supplemental file including IQRs of variables provided.

Table 3. The use of disease-modifying anti rheumatic drugs (DMARDs) in the Quest-RA countries; highest percentage for each drug indicated in bold, lowest in bold italics.

Country	Delay to start DMARDs, months, median	DMARD Exposure Years, mean	Selected DMARDs ever taken; percentage of patients in the QUEST-RA study per country.					
			Pred	MTX	HCQ	SSZ	LEF	Any Biologic
Denmark	10	7.9	43%	85%	39%	64%	11%	23%
Finland	7	14.4	74%	85%	74%	84%	21%	17%
France	8	9.9	83%	86%	55%	49%	42%	53%
Germany	15	8.4	54%	78%	30%	36%	25%	29%
Ireland	11	6.3	71%	92%	15%	33%	24%	41%
Italy	9	7.1	69%	79%	42%	14%	31%	26%
Netherlands	5	8.1	26%	91%	28%	35%	6%	19%
Poland	4	7.2	69%	87%	34%	60%	18%	8%
Spain	14	7.3	67%	82%	43%	29%	34%	27%
Sweden	12	8.8	66%	83%	34%	62%	9%	31%
UK	12	7.9	51%	67%	39%	46%	4%	16%
Turkey	12	8.9	69%	88%	27%	61%	22%	7%
Serbia	11	6.6	88%	69%	55%	17%	7%	2%
USA	9	7.9	77%	85%	49%	12%	19%	33%
Argentina	13	3.7	83%	68%	49%	6%	16%	3%
Total	9	8.1	66%	83%	41%	43%	21%	23%

Pred=prednisone, MTX=methotrexate, HCQ=hydroxychloroquine, SSZ=sulfasalazine, LEF=leflunomide

A supplemental file including standard deviation of DMARD exposure and IQR of delay to start DMARDs provided